Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
- 1.1k Downloads
Although several chemical structural classes of synthetic cannabinoids (SCs) were recently classified as Schedule I substances, rates of use and cases of serious toxic effects remain high. While case reports and media bring attention to severe SC toxicity, daily SC use resulting in dependence and withdrawal is a significant concern that is often overlooked when discussing the risks of these drugs. There is a rich literature on evidence-based approaches to treating substance use disorders associated with most abused drugs, yet little has been published regarding how to best treat symptoms related to SC dependence given its recency as an emerging clinically significant issue. This review provides a background of the pharmacology of SCs, recent findings of adverse effects associated with both acute intoxication and withdrawal as a consequence of daily use, and treatment approaches that have been implemented to address these issues, with an emphasis on pharmacotherapies for managing detoxification. In order to determine prevalence of use in cannabis smokers, a population at high risk for SC use, we obtained data on demographics of SC users, frequency of use, and adverse effects over a 3.5-year period (2012–2015) in the New York City metropolitan area, a region with a recent history of high SC use. While controlled studies on the physiological and behavioral effects of SCs are lacking, it is clear that risks associated with using these drugs pertain not only to the unpredictable and severe nature of acute intoxication but also to the effects of long-term, chronic use. Recent reports in the literature parallel findings from our survey, indicating that there is a subset of people who use SCs daily. Although withdrawal has not been systematically characterized and effective treatments have yet to be elucidated, some symptom relief has been reported with benzodiazepines and the atypical antipsychotic, quetiapine. Given the continued use and abuse of SCs, empirical studies characterizing (1) SCs acute effects, (2) withdrawal upon cessation of use, and (3) effective treatment strategies for SC use disorder are urgently needed.
KeywordsSpice K2 Synthetic cannabinoid Adverse effects Dependence Withdrawal Cannabis
This research was supported by the US National Institute on Drug Abuse Grants DA039123, DA036809, and DA02775. The authors acknowledge and appreciate Dr. Margaret Haney for the discussion and feedback throughout manuscript preparation and the exceptional assistance of Damaris Rocha, Vivian Mao, Nicole Ann Borchard, Ursula Rogers, Olivia Derella, Bennett Wechsler, Stephanie Rivera, Chananda Thavisin, Divya Ramesh, and Jorge Ginory-Perez for interviewing participants and data collection.
Compliance with Ethical Standards
All study procedures were approved by the Institutional Review Board of the New York State Psychiatric Institute and were in accord with the Declaration of Helsinki.
Conflict of Interest
Ziva D. Cooper is a non-compensated board member of KannaLife, Inc. and has received consultancy fees from PharmaCann, LLC. Dr. Cooper has received research funds from Insys Therapeutics.
Human and Animal Rights and Informed Consent
This manuscript does include data obtained from human subjects.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 1.Wehrman J. Fake marijuana spurs more than 2,500 calls to U.S. poison centers this year alone. Alexandra: American Association of Poison Control Centers; 2010.Google Scholar
- 2.United States Drug Enforcement Administration. Schedules of controlled substances: placement of five synthetic cannabinoids into Schedule I, 21 CFR Part 1308 [Docket No. DEA-345]. Fed Regist. 2012;77:12508–14.Google Scholar
- 3.United States Drug Enforcement Administration. DEA makes three more “fake pot” drugs temporarily illegal today. Washington: United States Department of Justice; 2013.Google Scholar
- 4.United States Drug Enforcement Administration. DEA news: huge synthetic drug takedown. Washington: United States Department of Justice; 2014.Google Scholar
- 5.United States Drug Enforcement Administration. Schedules of controlled substances: temporary placement of the synthetic cannabinoid MAB-CHMINACA into Schedule I. United States Department of Justice, Washington, D.C. 2015. Retrieved on November 11, 2015. http://www.deadiversion.usdoj.gov/fed_regs/rules/2015/fr0916_2.htm
- 8.New York City Department of Health and Mental Hygiene. Increase in synthetic cannabinoid (marijuana)-related adverse events and emergency department visits. April, 2015. http://www.nyc.gov/html/doh/downloads/pdf/ah/marijuana-alert.pdf. Accessed 20 November 2015.
- 9.New York City Department of Health and Mental Hygiene. Increase in synthetic cannabinoid (K2)-related adverse events and emergency department visits. September 2015. https://a816-health30ssl.nyc.gov/sites/nychan/Lists/AlertUpdateAdvisoryDocuments/Synthetic%20cannabinoids-HAN-advisory_Summer%202015%20-penultimate8.pdf. Accessed 20 November 2015.
- 10.Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014.Google Scholar
- 17.Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, et al. Repeated administration of phytocannabinoid Δ9-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacol Res. 2015;102:22–32.CrossRefPubMedGoogle Scholar
- 22.•Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sci. 2013;97:45–54. A comprehensive review of preclinical studies that demonstrate pharmacological differences between synthetic cannabinoids and THC that contribute to their enhanced toxic effects.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, et al. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol. 2012;83:952–61.CrossRefPubMedPubMedCentralGoogle Scholar
- 27.de Villiers P. Choice in concurrent schedules and a quantitative formulation of the law of effect. Handbook of Operant Behavior. 1977;233–287.Google Scholar
- 34.••Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, et al. Forensic investigation of K2, Spice, and “bath salt” commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int. 2013;233:416–22. This article describes findings from a forensic analyses of 3000 drug-related products confiscated over a three year period. This analysis describes the prevalence of synthetic cannabinoid compounds in confiscated items, and the wide range of compounds detected within and across products.CrossRefPubMedGoogle Scholar
- 36.••Hermanns-Clausen M, Kneisel S, Szabo B, Auwärter V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–44. This article provides a comprehensive description of acute toxic effects due to confirmed synthetic cannabinoid use including onset, duration, and severity of symptom, and symptom management as a function of specific synthetic cannabinoids detected by serum and urine toxicology.CrossRefPubMedGoogle Scholar
- 52.Rodgman CJ, Verrico CD, Worthy RB, Lewis EE. Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone. Prim Care Companion CNS. 2014;16:4.Google Scholar
- 53.••Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev. 2015;34:147–53. This article reports on demographics of a population presenting for treatment for problematic synthetic cannabinoid use, withdrawal symptoms, and treatment strategies.CrossRefPubMedGoogle Scholar